-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationFan Dongdong
This summer, the US Supreme Court refused to accept Sandoz and Amgen's patent dispute over its anti-inflammatory blockbuster Enbrel
According to the latest verdict, the U.
The update of this court decision marks the second patent setback for Enbrel biosimilars this year
According to the latest judgment, Samsung Bioepis will not be able to manufacture, sell or import Enbrel biosimilar drugs in the United States before 2029
Enbrel is the world's first TNF inhibitor used in rheumatoid arthritis and ankylosing spondylitis.
In terms of patents for other therapies, Amgen also recently requested the US Supreme Court to intervene and review its long-standing PCSK9 patent dispute with Sanofi and Regeneron
Reference source: Amgen stalls Samsung's Enbrel biosim until 2029 in 2nd patent win of the year